Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Vaxil Initiates Pre-Clinical Study in New Oncology Target V

<< Previous

Bullboard Posts

Next >>

Comment by superstockpickon Oct 13, 2020 2:25pm

82 Views

Post# 31708062

RE:RE:RE:RE:RE:RE:RE:RE:Vaxil Initiates Pre-Clinical Study in New Oncology Target V

*** The Press Release needs some work or updated ***

** The 3rd paragraph says " we are excited to partner with vaxil, and at the end of the paragraph it said " Mr.david

Then in the 5th paragraph David Gorens states he is proud to work with Ayelet David and
her team at Ben Gurion University

Is it a woman or a man ??? very confusing news release.

The 4th paragraph is the word prog r am, a better proof reading of te news releases would be nice

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features